National Breast Cancer Coalition Steps up Washington Lobbying

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

WASHINGTON--The National Breast Cancer Coalition (NBCC) has announced its intention to lobby against congressional forces that want to reduce NIH funding. The coalition thus allies itself with professional societies that lobby Congress to increase federal funding for biomedical research.

WASHINGTON--The National Breast Cancer Coalition (NBCC) has announcedits intention to lobby against congressional forces that wantto reduce NIH funding. The coalition thus allies itself with professionalsocieties that lobby Congress to increase federal funding forbiomedical research.

The Coalition also plans to draft legislation designed to protectthe privacy of individuals who test positive for the presenceof cancer genes so that their access to health insurance coveragewill not be put in jeopardy.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content